☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
brca-mutated advanced ovarian cancer
AstraZeneca and MSD's Lynparza (olaparib) Receive NMPA's Approval as 1L Maintenance Therapy for BRCA-Mutated Advanced Ovarian Canc...
December 5, 2019
AstraZeneca and Merck's Lynparza (olaparib) Receives FDA's Approval for 1L BRCA-Mutated Advanced Ovarian Cancer
December 20, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.